Additionally, a multivariate analysis of 38 patients with advanced non-small cell lung cancer with 32 paired serum samples revealed that follistatin (also known as activin-binding protein) and IFN-γ-inducible protein-10 (IP-10, also known as CXCL10) were statistically associated with durable clinic benefit defined by partial response and stable disease that lasted for more than 6 months while CCL5 (RANTES) was significantly associated with IRAEs onset. The gene discussed is CCL5; the disease is non-small cell lung carcinoma.